Please login to the form below

Not currently logged in
Email:
Password:

Biocon in drug development talks with Bayer

According to a report in the Indian newspaper, The Economic Times, biotechnology company, Biocon, is in discussions with German pharmaceutical company Bayer regarding the co-development of biotechnology drugs.

According to a report in the Indian newspaper, The Economic Times, biotechnology company, Biocon, is in discussions with German pharmaceutical company Bayer regarding the co-development of biotechnology drugs.

Biocon's managing director and chairman, Kiran Mazumdar-Shaw, told the newspaper that the agreement, which initially involved research activities, could also include biotech drug development activities.

Biocon, which has not commented on the report, derives much of its revenue from ethical drugs, such as head and neck cancer treatment, BioMab EGFR, as well as its enzyme business. The firm's strategy is to increase the share of research services business to a quarter of its total revenue in the next five years from about 15 per cent currently.

Bristol-Myers Squibb (BMS) revealed back in March 2007 that it was to partner with Biocon's research services unit, Sungene, and set up a facility in Bangalore to aid discovery and early drug development.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics